Scott Rollins, Ph.D.
Year 1: 858,350.00 Year 2: 879,500.00
Selexys Pharmaceuticals: Utilizing Oklahoma Resources to Develop a Novel Therapeutic for Chron's Diesase
Selexys Pharmaceuticals Corporation
Selexys Pharmaceuticals is developing a novel new drug to treat Crohn’s Disease, an inflammatory bowel disease. The antibody-based technology was discovered at the OUHSC and is exclusively licensed to Selexys. There is substantial data from animal models suggesting that treatment with these identified antibodies will have a profound therapeutic effect in humans. Selexys will manage the drug development, clinical trial planning and implementation; Cytovance Biologics will provide the GMP contract manufacturing services and the Oklahoma Foundation for Digestive Research will conduct the Phase I/II clinical trials.